title: Bifunctional amine-tethered ruthenium(II) arene complexes form monofunctional adducts on DNA.
abstract: The tethered RuII half-sandwich complexes [eta(6):eta(1)-C(6)H(5)(CH(2))(n)NH(2))RuCl(2)] 1 (n = 3) and 2 (n = 2) have been synthesized as potential bifunctional anticancer complexes, and their X-ray crystal structures have been determined. They hydrolyze rapidly in aqueous solution to give predominantly mono-aqua mono-chlorido species. Mono-9EtG adducts, where 9EtG = 9-ethylguanine, form rapidly, but the second 9EtG binds more slowly and more weakly. In the X-ray crystal structure of the di-9EtG adduct [(eta(6):eta(1)-C(6)H(5)(CH(2))(3)NH(2))Ru(9EtG)2](CF(3)SO(3))(2).H(2)O (8.H(2)O), one of the Ru-N7 bonds is significantly longer than the other (2.1588(18) vs 2.101(2) A). The bound guanine bases adopt a head-to-head configuration, stabilized by tether NH2 hydrogen bonding to C6O of 9EtG. The X-ray crystal structure of the dinitrato complex [(eta(6):eta(1)-C(6)H(5)(CH(2))(3)NH(2))Ru(NO(3))(2)] (3) showed both nitrates to be bound to ruthenium. This complex readily rutheniated calf thymus DNA but failed to produce stop sites on pSP73KB plasmid DNA during DNA transcription by an RNA polymerase. This suggested that only monofunctional DNA adducts formed, as did interstrand cross-linking assays. Also, the unwinding angle induced in negatively supercoiled DNA (9 +/- 1 degrees) was less than that induced by cisplatin (13 degrees). These findings may explain why complexes such as 1 and 2 exhibited low cytotoxicities (IC(50) values >100 microM) toward A2780 human ovarian cancer cells.
authors.affiliation: School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh, EH9 3JJ, U.K.
authors.forename: Michael
authors.initials: M
authors.lastname: Melchart
authors.forename: Abraha
authors.initials: A
authors.lastname: Habtemariam
authors.forename: Olga
authors.initials: O
authors.lastname: Novakova
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Moggach
authors.forename: Francesca P A
authors.initials: FP
authors.lastname: Fabbiani
authors.forename: Simon
authors.initials: S
authors.lastname: Parsons
authors.forename: Viktor
authors.initials: V
authors.lastname: Brabec
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Sadler
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D002417:Cattle; D002621:Chemistry / Q000379:methods*; D002945:Cisplatin / Q000494:pharmacology; D004247:DNA / Q000737:chemistry*; D018736:DNA Adducts / Q000737:chemistry*; D004278:DNA, Superhelical / Q000737:chemistry; D012321:DNA-Directed RNA Polymerases / Q000737:chemistry; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D020128:Inhibitory Concentration 50; D008956:Models, Chemical; D008968:Molecular Conformation; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017975:Ruthenium Compounds / Q000737:chemistry*; D013950:Thymus Gland / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D018736:DNA Adducts; D004278:DNA, Superhelical; D017975:Ruthenium Compounds; D004247:DNA; D012321:DNA-Directed RNA Polymerases; D002945:Cisplatin